NORWALK, Conn., May 3, 2016 /CNW/ -- Mederi Therapeutics Inc., manufacturers of Stretta Therapy for gastroesophageal reflux disease (GERD), today announced the launch of RFT3, the third generation of Stretta technology. The new product will be launched at Digestive Disease Week® (DDW) 2016, to be held May 21-24 in San Diego. Additionally, Stretta 10-year follow-up data on special patient populations with GERD will be presented in several DDW poster sessions.
The New Stretta RFT3 is a re-generation of the clinically proven Stretta system. While the procedure remains the same, new aesthetic, functional, and material improvements will further facilitate ease of use and optimal delivery of Stretta treatment for chronic GERD sufferers.
"We are constantly listening to our worldwide users and utilizing that feedback to make incremental improvements to our system," said Bob Knarr, CEO of Mederi. "The third generation of Stretta offers improved interfaces, and automation of certain features to enhance usability and optimize treatment. The new RFT3 catheters are compatible with the existing MDRF1 Generator, allowing maximum versatility of the updated technology. These enhancements demonstrate Mederi's ongoing commitment to quality products."
About 30% of adults suffer from chronic GERD. Many of these patients don't completely respond to proton pump inhibitors (PPIs), the most common medication for this condition, and many more are concerned about the risks associated with long-term PPI use, or anti-reflux surgery. Stretta provides a non-surgical, middle option for this patient.
Mederi will introduce and demonstrate the new Stretta RFT3 system in the ASGE Learning Center at DDW. Demonstrations will be held:
- Saturday, May 21: Hands-On 1:00-4:00 pm; Presentation 1:00-2:00 pm
- Sunday, May 22: Hands-On 8:00 am-12:00 pm; Presentation 9:00-10:00 am
- Monday, May 23: Hands-On 1:00-4:00 pm; Presentation 1:00-2:00 pm
- Tuesday, May 24: Hands-On 1:00-4:00 pm; Presentation 2:00-3:00 pm
At DDW, Stretta 10-year data from studies conducted by Dr. Mark Noar, Director of The Heartburn and Reflux Study Center in Towson, MD will be presented in several poster sessions. Three presentations will examine specific patient subsets from the previously published 10-year study, and analyze the effect of Stretta on patients with high Body Mass Index (BMI), respiratory symptoms of GERD, and patients with recurring GERD after anti-reflux surgery. "It's very important to have a non-surgical GERD treatment option for these challenging patient populations," noted Dr. Noar.
To learn more about the new Stretta RFT3 and the latest clinical data, please visit Mederi's booth 3349 at DDW 2016.
About Mederi Therapeutics Inc. and Stretta® Therapy
Mederi manufactures innovative non-surgical devices that use non-ablative radiofrequency (RF) energy to treat digestive diseases. Mederi's Stretta Therapy has been proven safe and effective for the treatment of GERD in more than 40 studies, all showing a high level of safety and efficacy and long-term symptom relief. More than 20,000 Stretta procedures have been performed worldwide, and it is available in more than 40 countries.
For more information go to: www.stretta-therapy.com.
Logo - http://photos.prnewswire.com/prnh/20160502/362660
SOURCE Mederi Therapeutics Inc.